酮咯酸用于假体乳房再造对住院时长与术后阿片类用药的影响
该回顾性研究纳入2012年1月至2016年12月间接受乳房切除后假体乳房再造的198例患者,比较使用与未使用酮咯酸者的术后阿片类用量和住院时长。结果显示使用酮咯酸者阿片类用量显著更少(80 mg vs 108.8 mg,P=0.002),住院时间更短(1.9天 vs 2.1天,P=0.04),提示酮咯酸可作为多模式镇痛的安全经济补充。
要点
- 使用酮咯酸者术后阿片类用量为80 mg,未使用者为108.8 mg(P=0.002)。
- 使用酮咯酸者住院时长为1.9天,未使用者为2.1天(P=0.04)。
- 酮咯酸或可作为假体乳房再造术后多模式镇痛的辅助调整。
核心结论
- 接受酮咯酸的患者住院时间更短且阿片类用量更低,提示酮咯酸可能是术后多模式镇痛中安全且具成本效益的调整。
研究设计与样本
- 回顾性研究,纳入2012年1月至2016年12月间接受乳房切除后假体乳房再造的患者,共198例符合纳入标准。
主要发现
- 使用酮咯酸者阿片类用量为80 mg,未使用者为108.8 mg(P=0.002)。
- 使用酮咯酸者住院时长为1.9天,未使用者为2.1天(P=0.04)。
- 慢性抗凝、阿司匹林或凝血病等其他危险因素被记录。
临床怎么用
- 在假体乳房再造术后可考虑将酮咯酸作为多模式镇痛方案的辅助用药,以减少阿片类用量并缩短住院时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid drugs have been a mainstay medication for the management of postoperative pain for several decades; however, in recent years there has been a push towards investigating alternative treatment options. Although ketorolac has been widely used by other medical and surgical specialties for analgesia, its utilization in plastic surgery has been widely debated. OBJECTIVES: The purpose of this study was to investigate the efficacy of ketorolac as an adjunct in postoperative pain management. METHODS: The authors performed a retrospective review of patients who underwent implant-based breast reconstruction after mastectomy between January 2012 and December 2016. Other risk factors, such as chronic anticoagulation, aspirin, or coagulopathies, were documented as well. RESULTS: There were 198 patients who met the inclusion criteria. The results demonstrated that patients who received ketorolac utilized significantly fewer narcotics than patients who did not: 80 mg vs 108.8 mg (P = 0.002), respectively. The results showed that patients who received ketorolac had a decreased length of hospitalization: 1.9 days vs 2.1 days (P = 0.04), respectively. CONCLUSIONS: Generous narcotic prescribing has received greater scrutiny in recent years. Aside from the risk of increased narcotic availability in the community, the side effects of nausea, puritis, and constipation delay patient recovery. These data show that patients who received ketorolac have a decreased length of hospital stay and lower narcotic use, suggesting ketorolac may be a safe and cost-effective adjustment to a multi-modal pain control regimen postoperatively.
引用
- Nguyen BN, Barta RJ, Stewart CE, et al. Ketorolac for Patients Undergoing Implant-Based Breast Reconstruction: Impact on Hospital Length of Stay and Postoperative Narcotic Use. Aesthet Surg J. 2020. PMID: 31250006. doi:10.1093/asj/sjz179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。